Literature DB >> 11181407

Segmental expression of somatostatin receptor subtypes sst(1) and sst(2) in tubules and glomeruli of human kidney.

D A Balster1, M S O'Dorisio, M A Summers, M A Turman.   

Abstract

Somatostatin is known to modulate mesangial and tubular cell function and growth, but the somatostatin receptor (sst) subtypes responsible for these effects have not been defined. There are at least five different sst receptor subtypes (sst(1)-sst(5)). We used RT-PCR to demonstrate that normal human kidney consistently expresses mRNA for sst(1) and sst(2) (9 of 9 donors). Some donors expressed sst(4) or sst(5) mRNA, but none expressed sst(3) mRNA. Expression of sst(1) and sst(2) was further assessed by staining serial sections of normal human kidney with sst(1) and sst(2) antisera, Arachis hypogaea (AH) lectin (to define distal tubule/collecting duct cells), Phaseolus vulgaris lectin (proximal tubules), and Tamm-Horsfall protein (THP) antiserum (thick ascending limb of the loop of Henle). Specificity of antisera was demonstrated by transfection and absorption studies. Sst(2), but not sst(1), was expressed in glomeruli. Intense sst(1) and sst(2) staining localized exclusively to AH+ and THP+ tubules. Thus sst(1) and sst(2) subtype-selective analogs may be useful to beneficially modulate renal cell function in pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181407     DOI: 10.1152/ajprenal.2001.280.3.F457

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  18 in total

1.  Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma.

Authors:  Roberta Mazzucchelli; Doriana Morichetti; Marina Scarpelli; Aldo V Bono; Antonio Lopez-Beltran; Liang Cheng; Ziya Kirkali; Rodolfo Montironi
Journal:  Asian J Androl       Date:  2010-12-13       Impact factor: 3.285

2.  Activation and involvement of p53 in cisplatin-induced nephrotoxicity.

Authors:  Qingqing Wei; Guie Dong; Tianxin Yang; Judit Megyesi; Peter M Price; Zheng Dong
Journal:  Am J Physiol Renal Physiol       Date:  2007-08-01

3.  Cubilin and megalin in radiation-induced renal injury with labelled somatostatin analogues: are we just dealing with the kidney?

Authors:  R Moncayo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10       Impact factor: 9.236

4.  Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.

Authors:  Jingjing Zhang; Hao Wang; Orit Jacobson; Yuejuan Cheng; Gang Niu; Fang Li; Chunmei Bai; Zhaohui Zhu; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2018-04-13       Impact factor: 10.057

Review 5.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

6.  Guanosine supplementation reduces apoptosis and protects renal function in the setting of ischemic injury.

Authors:  K J Kelly; Z Plotkin; P C Dagher
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

7.  Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer.

Authors:  Roberta Mazzucchelli; Doriana Morichetti; Alfredo Santinelli; Marina Scarpelli; Aldo V Bono; Antonio Lopez-Beltran; Liang Cheng; Rodolfo Montironi
Journal:  Cell Oncol (Dordr)       Date:  2011-04-30       Impact factor: 6.730

8.  Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney.

Authors:  Sunil Bhandari; Neil Watson; Ervine Long; Steve Sharpe; Wenwen Zhong; Shang-Zhong Xu; Stephen L Atkin
Journal:  J Histochem Cytochem       Date:  2008-04-28       Impact factor: 2.479

Review 9.  Vasopressin antagonists in polycystic kidney disease.

Authors:  Vicente E Torres
Journal:  Semin Nephrol       Date:  2008-05       Impact factor: 5.299

Review 10.  Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues.

Authors:  Edgar J Rolleman; Marleen Melis; Roelf Valkema; Otto C Boerman; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-14       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.